INTRODUCTION
The three echinocandins, anidulafungin, caspofungin and micafungin, have been available for a decade. They display in-vitro fungicidal activity against most Candida spp., attractive tolerability and pharmacokinetic profiles, and have been recommended as first-line agents for invasive candidiasis [1] [2] [3] [4] [5] [6] . The echinocandins exhibit their antifungal activity via inhibition of the enzyme glucan synthase encoded by three related genes (FKS1, FKS2 and FKS3). Most Candida spp. are considered good targets. However, some Candida spp. are inherently less susceptible in vitro because of naturally occurring polymorphisms in the target protein (Table 1) [7] . For example, the echinocandin minimum inhibitory concentration (MIC) is approximately seven-fold higher against C. parapsilosis, which has a naturally occurring alteration in the target gene (Table 1) . Following regulatory approval, the use of the echinocandins for prophylaxis and treatment has grown substantially. A consequence of enhanced drug exposure is increased selection pressure for resistance and indeed an altered species distribution for invasive infections has been linked to the echinocandin use [8] . Moreover, reports on acquired echinocandin resistance, defined as resistance among species that are normally susceptible, have emerged and today acquired resistance has been reported in single isolates belonging to most Candida spp., including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis [9] [10] [11] [12] [13] [14] [15] . Elevated MICs have been associated with a number of single amino acid substitutions caused by mutations in specific 'hot spot' regions of the well conserved target genes FKS1 for all Candida spp., as well as FKS2 for C. glabrata (Table 1 ) [16] . The position, as well as the specific amino acid substitution, determines the degree of MIC elevation in the individual isolate.
The aim of this review is to present an up-to-date overview of echinocandin resistance in Candida by addressing the current epidemiology, the underlying molecular mechanisms and their differential impact on susceptibility and fitness, methods for resistance detection and the potential implication of increasing echinocandin resistance on treatment strategies of invasive candidiasis.
EPIDEMIOLOGY
Quite soon after the introduction of the echinocandins, it was noted that their increasing use was accompanied by epidemiological shifts with a proportional or numeric increase in the less susceptible C. parapsilosis at several centres [8, 17, 18] . Subsequently, the number of reports of acquired echinocandin resistance has attracted attention. Most are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible [9] [10] [11] [12] [13] [14] [15] . Although some cases are reported after short-term use (a week) [13, 19] , most
KEY POINTS
Echinocandin resistance in Candida is emerging in most clinically relevant Candida spp. but is particularly common in C. glabrata.
A wide range of hot spot mutations in the FKS target genes have been characterized and their impact on MIC and fitness described.
Reference antifungal susceptibility testing can reliably identify resistant isolates.
New methodologies that include molecular techniques and MALDI-TOF are being developed for detection of resistant isolates. Antifungal stewardship including efforts to limit longterm echinocandin exposure is recommended. cases are diagnosed after 3-4 weeks of therapy or even later [12,20 & ,21] . Resistance is more often found in C. glabrata, although this species is less frequent than C. albicans as a cause of invasive infections and has been reported on both sides of the Atlantic Ocean ( Fig. 1) [21, 22] . Whether this is due to a higher potential for developing resistance mutations or it relates to patients with C. glabrata infections who more often receive prolonged echinocandin therapy due to the intrinsic reduced susceptibility to azoles such as fluconazole remains to be understood. Nevertheless, resistance in C. glabrata is on the rise. This was recently documented in a 10-year survey at the Duke University Hospital in which the echinocandin resistance rate increased from 4. of such cases, as only the initial blood isolate is included to avoid biasing the data set, which is sound from an epidemiological point of view. Notably, it was recently reported that echinocandin resistance was detected in as many as 10% of posttreatment oral mucosal isolates obtained from candidaemic patients initially treated with an echinocandin [24 && ]. The use of echinocandins as first-line agents for candidaemia has unquestionably improved outcome for patients infected with a susceptible isolate [1] . However, there is solid documentation that the outcome for patients with increased MICs is significantly poorer. Not only has an unsuccessful outcome been reported in most case reports, but it was also documented in two recent studies that 80 and 78.5% candidaemia patients with an echinocandin-resistant C. glabrata isolate fail therapy, respectively [23
MECHANISMS AND IMPACT OF THE MIC
Intrinsic target gene alterations are found in C. parapsilosis, C. metapsilosis, C. orthopsilosis, C. guilliermondii and C. lipolytica (Table 1) [7, 26] . Additionally, polymorphisms occur at codon I660 in hot spot 1 of FKS1 in C. krusei, for which the in-vitro micafungin MIC is elevated approximately two-fold and at codon V641 in FKS1 and V1374 in FKS2 in Saccharomyces cerevisiae, which is, in general, slightly less echinocandin susceptible than C. albicans and C. glabrata. The potential impact of these polymorphisms for therapeutic response remains unclear (Table 1) . Acquired FKS alterations are most commonly substitutions, but deletions and stop codons have also been reported in C. glabrata (Table 1) [16, 21] . The degree of the MIC elevation depends on the position as well as the specific amino acid substitution. The most significant MIC elevation is found for alterations involving the first and fifth amino acid [F (phenylalanine) and S (serine)], respectively, in the hot spot 1 regions of the FKS1 or FKS2 target genes (Tables 1 and 2 ). FKS alterations in most cases confer cross-resistance to all three echinocandins. However, some alterations cause more moderate MIC elevations and not always for all three compounds ( Table 2 ). For example, the F659-DEL in C. glabrata confers resistance to all three echinocandins, whereas the F659S substitution at the same codon gives rise to anidulafungin and caspofungin resistance, whereas the micafungin MIC and in-vivo efficacy in a murine animal model remain unchanged [ 
IMPLICATION ON FITNESS
Resistance mutations often come at a fitness cost, and when that is the case, it may limit the spread of the organism because of competition from wild-type isolates when therapy is discontinued. Echinocandin resistance in Candida has been linked to loss of fitness for homozygous Fks1p F641 and S645 mutants of C. albicans and Fks2p S663P mutants of C. glabrata [31] [32] [33] . Thus, mutations at these hot spots have been linked to the following: first, impaired enzyme capacity; second, altered cell wall composition, that is reduced glucan and increased chitin content; third, increased cell wall thickness; and fourth, impaired filamentation properties, which contribute to a lower growth rate in vitro and in vivo in Drosophila and mouse models [31] [32] [33] . Similarly, Lackner et al. [34 && ] found reduced kidney burden comparing sequential C. albicans clinical isolates with and without two heterogenous mutations simultaneously at position R647 and P649. In contrast, Borghi et al. [35] found no significant difference in virulence or fitness when comparing sequential patient C. glabrata isolates with and without the S663P mutation in the Galleria mellonella larvae model. Either this contradictory finding relates to the different virulence models used, that is larvae versus mouse models, or alternatively, it may be explained by differences in the fitness reduction in the two isolates investigated in these studies. Indeed, whole genome sequencing of a series of clinical C. glabrata isolates revealed that a subsequent compensatory mutation (CDC55 P155S) mitigated the fitness cost induced by the S663P mutation [32] .
DETECTION OF RESISTANCE
Detection of echinocandin resistance can be assessed phenotypically, using microbroth dilution, Etest (bioMérieux, Marcy l'Etoile, France) or disk diffusion or semiautomated systems such as the VITEK system (bioMérieux) or it can be done molecularly by detection of mutations in the hot spot regions of the FKS1 and FKS2 (C. glabrata only) genes. Additionally, preliminary studies have exploited the adoption of matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) for resistance detection. These options and comments regarding pros and cons will be discussed below.
MICRODILUTION REFERENCE TESTING AND COMMERCIAL PHENOTYPIC SUSCEPTIBILITY TESTS
The two organizations, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), have established reproducible and reliable microbroth dilution susceptibility tests for Candida and echinocandins [36,37,38 && ]. Apart from being the commercial reference method against which susceptibility tests are standardized, these reference methods have proven reliable and useful in mycology reference laboratories for the detection of resistance in referred clinical isolates. Recently, EUCAST breakpoints were developed for anidulafungin and micafungin and the former CLSI breakpoints were revised providing species-specific breakpoints for all three echinocandins and their value confirmed [ 43, 44,45 & ]. Thus, almost 20% of C. glabrata isolates and more than a third of the C. krusei isolates were anidulafungin and micafungin susceptible but caspofungin nonsusceptible [44,45 & ]. This may in part be associated with variability in the caspofungin used for in-vitro testing [46] . Consequently, anidulafungin and micafungin have been evaluated as markers for caspofungin susceptibility and found appropriate for this purpose and is recommended also by EUCAST [40
The Sensititre Yeast One system was recently evaluated in a multicentre study using consecutive samples received in each of eight laboratories. Overall, a good interlaboratory agreement was achieved and the resistance rates reported for anidulafungin and micafungin were within the expected range (4.3 and 4.4% for anidulafungin and micafungin, respectively) [45 & ]. Few studies have systematically evaluated the commercial susceptibility test systems for their ability to correctly discriminate between susceptible wild-type isolates and those bearing FKS resistance mutations by including a sufficient number of mutant isolates. In one such study evaluating the performance the VITEK system for caspofungin susceptibility, a relatively high number (19.4%) of mutant isolate were misclassified as susceptible [49 && ]. This finding, coupled with the fact that the system could not discriminate intermediate from susceptible C. glabrata isolates because the caspofungin concentration used in the system does not encompass the breakpoint, renders it less useful in its current form despite being very user friendly. Hence, although commercial testing has become available for most antifungal compounds, including the echinocandins, some challenges remain to be addressed. Therefore, any laboratory wishing to perform antifungal susceptibility testing using one of these systems must ensure that the MIC values generated for wild-type isolates match the wild-type distributions used for the clinical breakpoint setting, before adopting the reference breakpoints [38 && ].
MOLECULAR APPROACHES
So far, clinically relevant acquired echinocandin resistance in Candida has never been detected in the absence of FKS hot spot mutations. Hence, an attractive approach is to apply molecular tools for the detection of echinocandin resistance. Target gene sequencing has become increasingly available and appropriate primers have been designed and published for the most common species [9] [10] [11] [12] [13] [14] [15] . The drawback, however, is the associated cost and as the procedure is time consuming unless automated. Various PCR formats focussing specifically on the detection of mutations in C. glabrata have been developed [50 && ,51 && ]. The obvious benefit of such assays is that they allow a rapid detection of resistance in the species in whom resistance most often occur. The challenges are that a correct identification to the species level is required for selection of appropriate methodology and that knowledge regarding the species and compound-dependent differential impact on the susceptibility is required to separate mutations associated with therapeutic failure from those that may respond to one or several echinocandins. Finally, none of these methods is yet commercially available and, therefore, implementation requires molecular biology expertise and in-house validation.
MATRIX-ASSISTED LASER DESORPTION IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
Recently, the potential of using MALDI-TOF detection of proteome changes after a 15-h exposure of fungal cells to serial drug concentrations was described for the determination of antifungal susceptibility [52] . It was followed by a simplified version, which facilitated discrimination of susceptible and resistant isolates of C. albicans after only 3 h of incubation in the presence of two 'breakpoint' level drug concentrations (0.03 and 32 mg/l) of caspofungin [53 && ]. Categorizations determined using MALDI-TOF mass spectrometrybased antifungal susceptibility testing (AFST) were consistent with the wild-type and mutant FKS1 genotypes and the AFST reference methodology. Although it remains to be investigated how this approach can be extended to include other species with different growth kinetics and species-specific clinical breakpoints, the prospect of a 'same-day' susceptibility screening test is indeed attractive.
CLINICAL IMPLICATIONS
The increasing incidence of echinocandin-resistant Candida isolates is a reason for concern, as it leads to the emergence of multidrug-resistant organisms that present limited, if any, treatment options. This is particularly true for the emergence of echinocandin resistance in C. glabrata, an organism that is commonly resistant to azole drugs and for which amphotericin B is, therefore, the only therapeutic alternative. Echinocandin resistance often develops in a progressive manner. Resistant isolates can be detected in the oral flora postcandidaemia treatment at a rate of approximately 10% often in coexistence with susceptible isolates but is detected at a lower rate and apparently typically later (3-4 weeks) among blood isolates [12, 21, 24 && ]. Unlike the azoles, echinocandins are not used in the primary healthcare sector or for plant and material protection. Therefore, antifungal stewardship in the hospital is of utmost importance in order to minimize the selection pressure when possible. A step-down approach has been recommended in the new European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the management of invasive candidiasis [2] [3] [4] [5] . On the basis of the data from initial controlled trial, ESCMID recommended deescalation after 10 days, as data were not available supporting any earlier timepoint [54] . Recently, early step-down after 5 days of echinocandin therapy was found efficacious in an open-label study in patients meeting the prespecified criteria (ability to tolerate oral therapy; afebrile for more than 24 h; haemodynamically stable; not neutropenic and with a documented clearance of Candida from the bloodstream) [55 && ]. This may suggest that early deescalation is a reasonable approach at least in this category of patients. It is well recognized that the clinical situation may indicate that longer treatment is necessary and that voriconazole or highdose fluconazole may not be attractive alternatives in severely ill patients with C. glabrata candidaemia. Careful monitoring for antifungal resistance in invasive and colonizing samples should be performed when echinocandin therapy is prescribed for longer time periods. Moreover, strategies involving alternating therapy (echinocandin and amphotericin B) or periods with combination therapy might potentially be alternative options that deserve further investigation.
CONCLUSION
Echinocandin resistance is emerging in populationbased candidaemia surveys and particularly in severely ill patients receiving longer term therapy. It is particularly challenging with C. glabrata in which the alternative treatment options are limited. The outcome for patients with resistant isolates on echinocandin therapy is dismal. Therefore, early detection is vital. Antifungal susceptibility testing has been optimized over the recent years and should be available real time for centres managing high-risk patients. However, further work is needed in order to optimize susceptibility testing in the routine setting using commercial test formats. New modalities including molecular and MALDI-TOF detection are under development and appear promising for future implementation in clinical microbiology laboratories. Antifungal stewardship is an important tool reducing unnecessary use and the treatment duration whenever clinically indicated may help reducing the selection pressure and thus reverting the rise in resistance. Potentially, strategies involving alternating or combination therapy might deserve clinical evaluation for patients requiring long-term antifungal treatment with Candida coverage in order to avoid selection of resistance to this important drug class. Preliminary data demonstrating a notably high prevalence of echinocandin resistance (9.2%) in oral isolates from patients after treatment for candidaemia, demonstrating a higher potential for rapid resistance selection than presented in epidemiological candidaemia studies in which only initial isolates are included. 25.
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